Search results
Results from the WOW.Com Content Network
Apremilast was approved for use in the European Union in January 2015. [6] Generic versions of the medication are available in Canada. [32] In April 2023, an American court case confirmed Amgen's patents on Otezla until 2028, delaying the introduction of generics until at least that date. [33]
Apremilast, a phthalimide derivative that was approved by the U.S. FDA in March 2014 for use as a treatment for psoriatic arthritis, [21] and in September 2014 for the treatment of plaque psoriasis under the brand name Otezla. [22] Cilomilast, in clinical development by GlaxoSmithKline for treatment of COPD. [23]
The FDA has approved Amgen Inc's (NASDAQ: AMGN) Otezla (apremilast) to treat adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. With this expanded ...
The FDA also approved Amgen's Otezla for adults with plaque psoriasis of any severity level. [ 105 ] 2022: In January, Amgen announced a research collaboration with Generate Biomedicines across multiple modalities and several therapeutic areas for up to $1.9 billion.
Stock in Idera Pharmaceuticals tanked this week when Celgene announced that the FDA approved Otezla (apremilast) for psoriatic arthritis, a major competitor of Idera's Phase II candidate, IMO-8400.
Drugmaker Bristol-Myers Squibb rose 3% following the FDA's approval of its psoriasis drug late on Friday. Share of rival Amgen, maker of the psoriasis drug Otezla, dropped 4%.
The deal was approved by shareholders in April 2019. [42] In August 2019, Amgen announced it would acquire the Otezla drug programme from Celgene for $13.4 billion, as part of Celgene and Bristol-Myers Squibb's merger deal. The Bristol-Myers acquisition closed on November 20, 2019. [43]
For premium support please call: 800-290-4726 more ways to reach us